HONG KONG, Dec. 17, 2025 — Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) (“HKPD” or the “Company”), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that all proposals at the Company’s 2025 annual meeting of stockholders, held on December 12, 2025 (local time), were duly approved. The Company’s shareholders passed and ratified the following proposals:
Proposal No. 1: The re-election of five directors—Chenyu Liang, Lap Sun Wong, Mike Yao Zhou, Jingyan Wu, Dr. Kam Leung Chan—each to serve until the 2026 Annual Meeting of Stockholders;
Proposal No. 2: The ratification of the appointment of Onestop Assurance PAC as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2026;
Proposal No. 3: The increase of the Company’s authorized share capital from US$100,000 (comprising 100,000,000 ordinary shares with a par value of $0.001 each) to US$1,000,000 (comprising 1,000,000,000 ordinary shares with a par value of US$0.001).
Proposal No. 4: The re-designation and reclassification of ordinary shares from a single class to Class A ordinary shares and Class B ordinary shares.
Proposal No. 5: The approval and implementation of the Reverse Share Split and Share Consolidation of the Company’s issued and outstanding Ordinary Shares.
Proposal No. 6: The change of the Company’s name from “Hong Kong Pharma Digital Technology Holdings Limited” to “Cellyan Biotechnology Co., Ltd” and the change of the Company’s foreign name from “港药数字科技控股有限公司” to “生研生物公司”.
Proposal No. 7: The adoption of the fourth amended and restated memorandum and articles of association of the Company.
Proposal No. 8: The repurchase by the Company of 7,150,000 Class A Ordinary Shares registered under TUTU Business Services Limited and the issuance of Class B Ordinary Shares;
Proposal No. 9: The adoption and approval of the Hong Kong Pharma Digital Technology Holdings Limited 2025 Equity Incentive Plan;
For the full text of the above proposals approved at the 2025 AGM, refer to the Form 6-K filed with the SEC on December 17, 2025.
About Hong Kong Pharma Digital Technology Holdings Limited
Hong Kong Pharma Digital Technology Holdings Limited provides two primary service categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services via its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited (“Joint Cross Border”), and (ii) OTC pharmaceutical cross-border procurement and distribution via its Hong Kong subsidiary, V-Alliance Technology Supplies Limited.
Through collaboration with OTC pharmaceutical suppliers, logistics firms, and merchants on Chinese e-commerce platforms, Joint Cross Border delivers a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products from outside Mainland China.
Joint Cross Border’s comprehensive service offerings include pre-consultation, product information review, procurement of overseas OTC pharmaceutical products, registration of products with the Hong Kong Department of Health, acquisition of import and export permits, product storage, packaging, and arrangement of logistics and end-to-end delivery services for customers.
For more information, please visit the Company’s website: .
Forward-Looking Statements
All forward-looking statements, whether express or implied, in this release are based solely on information currently available to us and only reflect the situation as of the date they are made. Investors can identify many (though not all) of these statements through terms such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or similar expressions in this release. Unless required by applicable law, we disclaim any obligation to publicly update any forward-looking statement to reflect events or conditions occurring after the date of this release. These statements are subject to uncertainties and risks, including—without limitation—uncertainties related to market conditions and other factors discussed in our filings with the SEC. Although the Company believes the expectations reflected in these forward-looking statements are reasonable, it cannot guarantee such expectations will be realized, and the Company warns investors that actual results may differ materially from expected results. Investors are encouraged to review other factors that may impact future results in the Company’s SEC filings. Additional factors are discussed in the Company’s SEC filings, which are available for review at .
For investor and media inquiries please contact:
Hong Kong Pharma Digital Technology Holdings Limited
Media Contact:
Investor Relations: stella @cell-yan.com
